bluebird bio, Inc

bluebird bio, Inc., based in Somerville, MA, is dedicated to developing curative gene therapies aimed at providing patients and their families with improved health outcomes. With a focus on conditions such as Beta-Thalassemia, Cerebral Adrenoleukodystrophy, and Sickle Cell Disease, the company is at the forefront of advancing gene therapy technologies, including their recently FDA-approved one-time treatment for sickle cell disease.

With over a decade of experience, bluebird bio boasts the largest and most comprehensive ex-vivo gene therapy data set globally. Their innovative approach utilizes proprietary lentiviral vector gene therapies designed to deliver functional copies of genes directly to patients' own cells, marking a significant advancement in the treatment of genetic disorders.

Generated from the website